» Authors » N A Chronos

N A Chronos

Explore the profile of N A Chronos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 350
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Coussement P, De Leon H, Ueno T, Salame M, King 3rd S, Chronos N, et al.
Circulation . 2001 Nov; 104(20):2459-64. PMID: 11705825
Background: Long-term biological effects of ionizing radiation on coronary arteries remain poorly defined. We examined late arterial responses 6 months after balloon angioplasty and beta-radiation in normal pig coronary arteries....
2.
Verheye S, Coussement P, Salame M, Fallahi P, Cui J, Chronos N, et al.
Int J Radiat Oncol Biol Phys . 2001 Nov; 51(3):820-7. PMID: 11697328
Purpose: To evaluate high-dose external beam irradiation (EBRT) in a pig coronary stent preparation because low and intermediate-dose EBRT failed to show inhibition of neointima formation in stented animal models....
3.
Karwatowski S, Chronos N, Sinclaire H, Forbat S, St John Sutton M, Black C, et al.
J Cardiovasc Magn Reson . 2001 Sep; 2(2):109-17. PMID: 11547800
The aim of this study was to assess the effect of scleroderma on left ventricular mass and subendocardial function using cardiovascular magnetic resonance (CMR) to determine parameters reflecting early dysfunction...
4.
Markou C, Chronos N, Hanson S
Thromb Haemost . 2001 Apr; 85(3):488-93. PMID: 11307820
Thromboembolic complications have been attributed to the use of radiographic contrast media (CM) during interventional procedures for arterial revascularization. However, due to the low frequency of adverse events, comparisons between...
5.
Bush M, Samara E, Whitehouse M, Yoshizawa C, Novicki D, Pike M, et al.
J Clin Pharmacol . 2001 Apr; 41(4):378-85. PMID: 11304894
Fibroblast growth factor-2 (FGF-2) is a heparin-binding protein capable of inducing angiogenesis in multiple animal models of chronic ischemia. The pharmacokinetics and pharmacodynamics of a single dose of recombinant FGF-2...
6.
Salame M, Verheye S, Crocker I, Chronos N, Robinson K, King 3rd S
Eur Heart J . 2001 Apr; 22(8):629-47. PMID: 11286520
No abstract available.
7.
Laham R, Chronos N, Pike M, Leimbach M, Udelson J, Pearlman J, et al.
J Am Coll Cardiol . 2000 Dec; 36(7):2132-9. PMID: 11127452
Objectives: Evaluate the safety, tolerability and preliminary efficacy of intracoronary (IC) basic fibroblast growth factor (bFGF, FGF-2). Background: FGF-2 is a heparin-binding growth factor capable of inducing functionally significant angiogenesis...
8.
Simons M, Bonow R, Chronos N, Cohen D, Giordano F, Hammond H, et al.
Circulation . 2000 Sep; 102(11):E73-86. PMID: 10982554
The rapid development of angiogenic growth factor therapy for patients with advanced ischemic heart disease over the last 5 years offers hope of a new treatment strategy based on generation...
9.
Verheye S, Markou C, Salame M, Wan B, King 3rd S, Robinson K, et al.
Arterioscler Thromb Vasc Biol . 2000 Apr; 20(4):1168-72. PMID: 10764689
Biocompatible stent coatings may alleviate problems of increased (sub)acute thrombosis after stent implantation. Hyaluronic acid (HA), a ubiquitous, nonsulfated glycosaminoglycan, inhibits platelet adhesion and aggregation and prolongs bleeding when administered...
10.
Ishiwata S, Verheye S, Robinson K, Salame M, De Leon H, King 3rd S, et al.
J Am Coll Cardiol . 2000 Apr; 35(5):1331-7. PMID: 10758977
Objectives: We evaluated the effect of orally administered tranilast, N-(3,4-dimethoxycinnamoyl) anthranilic acid, on histologic and histomorphometric changes after angioplasty or stent implantation in pig coronary arteries. Background: Tranilast, which has...